ALLMedicine™ Neuroblastoma Center

Mar 19th, 2023 - Clostridium perfringens ε-toxin (ETX) is the main toxin leading to enterotoxemia of sheep and goats and is classified as a potential biological weapon. In addition, no effective treatment drug is currently available in clinical practice for this t...

Mar 18th, 2023 - Renovascular hypertension (RVH) is a common cause of secondary hypertension. However, there have been no reports on RVH due to radiation-induced abdominal aorta stenosis after renal autotransplantation. A 27-year-old woman with a history of neurob...

Mar 18th, 2023 - Nested is defined as "cellular clusters arranged in small groupings with intervening vascular or stromal networks, lacking lumens or glandular formation." Using this definition, multiple neoplastic and non-neoplastic lesions of the head and neck c...

Mar 18th, 2023 - Background: Commonly, pediatric solid tumors occur independently. Only two patients with synchronous hepatoblastoma (HBL) and neuroblastoma (NBL) have been reported. Case reports: Two Chinese infants presented with abdominal mass at 10 and 8 month...

Mar 16th, 2023 - Practice Essentials Secondary lung tumors are neoplasms that spread from a primary lesion. The primary tumor can arise within the lung or outside the lung, with the metastases traveling through the bloodstream or lymphatic system or by direct exte...

Apr 30th, 2009 - Disseminating disease is a predictive and prognostic indicator of poor outcome in children with neuroblastoma. Its accurate and sensitive assessment can facilitate optimal treatment decisions. The International Neuroblastoma Risk Group (INRG) Task...

Mar 10th, 2023 - High risk neuroblastoma is an aggressive and lethal pediatric solid tumor. Survival remains less than 50% and those patients who do survive suffer many treatment-related acute and chronic toxicities, stressing a critical need for novel tumor-targe...

Mar 9th, 2023 - 9-ING-41 is a first-in-class, intravenously administered, maleimide-based, small molecule, potent selective GSK-3β inhibitor with significant pre-clinical and clinical anticancer activity. In the ongoing Actuate 1801 study in a cohort of over 90 p...

Mar 9th, 2023 - One 131I-omburtamab treatment cycle takes 4 weeks and includes a treatment dose, and an observation period and post-treatment evaluations. One 131I-omburtamab treatment cycle for Japan only takes 5 weeks and includes a dosimetry dose (2mCi) of 131...

Mar 9th, 2023 - PRIMARY OBJECTIVE: I. To determine whether administration of eflornithine hydrochloride (eflornithine [DFMO]) in combination with dinutuximab, irinotecan hydrochloride (irinotecan) and temozolomide results in an improved response rate compared to ...

Mar 9th, 2023 - 9-ING-41 is a first-in-class, intravenously administered, maleimide-based small molecule potent selective GSK-3β inhibitor with significant pre-clinical antitumor activity. GSK-3 is a serine/threonine kinase initially described as a key regulator ...

Dec 2nd, 2022 - Roche/Genentech will voluntarily withdraw accelerated approval of atezolizumab (Tecentriq) for advanced bladder cancer. The move follows the failure of a phase III trial to show a benefit in overall survival. Cryotherapy proved more effective than...

Dec 2nd, 2022 - (Reuters) - The U.S. health regulator on Thursday declined to approve a treatment from Y-mAbs Therapeutics for a rare form of nerve cancer in pediatric patients, dragging the company's shares down 16% in extended trading. Y-mAbs said it is assessi...

Oct 31st, 2022 - Y-mAbs Therapeutics has suffered a setback in its efforts to win US approval for I-omburtamab to treat a rare pediatric cancer. On October 28, a Food and Drug Administration (FDA) advisory panel found a lack of evidence to support the drug's appro...

Oct 28th, 2022 - An FDA advisory committee voted unanimously against recommending approval of the radiolabeled monoclonal antibody 131I-omburtamab for progressive neuroblastoma with central nervous system (CNS)/leptomeningeal metastases. Citing perceived shortcomi...

Oct 27th, 2022 - The FDA has expressed concern about the efficacy of 131I-omburtamab prior to a meeting of the regulatory agency’s Oncologic Drugs Advisory Committee (ODAC) to examine data supporting the biologic license application (BLA) seeking the agent’s appro...